anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Natural substances containing free or combined silica are treated in aqueous suspension at 150-280 DEG  C. under elevated pressure with an alkaline earth metal hydroxide, the solid : liquid ratio in the suspension being at most 1 : 6, whereby improved silicate products are obtained, which are used to thicken liquids.  In a modification, the products are after-treated with an acid or acidic agent, e.g. sulphur dioxide or carbon dioxide, to form neutral or acid silicates, or silica.  Initial materials mentioned are clay (bentonite), kaolin, loam, sand, kieselguhr and quartz powder; in the examples, the hydrothermal process used is that described in Specification 804,834. Liquids may in general be thickened until they are of a paste-like consistency or are in the form of powders, but acid liquids are not successfully thickened.  The silicate or silica may be mixed with other thickening agents such as pyrogenically prepared oxides, and may be loaded with an organic amine or alcohol.  They may be used in an amount of only 10 per cent.  Liquids referred to are paraffins, waxes, resins, bitumens, asphalts and sealing tars, in addition to liquid soap solutions (e.g. soft soaps), bleaching agents and detergents for dry bleaching, oils and liquid greases for solid lubricants or gel greases and the liquids used in lacquers.  When used in the latter compositions, the settling of pigments and fillers is delayed, and a matting effect is obtained. Examples refer to (1) the thickening of water, by materials obtained from bentonite and quartz, some of which were subsequently extracted with hydrochloric acid; (2) thickening of paraffin oil with acid-extracted bentonite and quartz products and an unextracted quartz product; (3) sedimentation retarding of lithopone with and without blancfixe and of micaceous iron ore, in lacquer linseed oil media, with acid-extracted bentonite and sand products.ALSO:Adhesives are thickened and sedimentation of fillers, e.g mineral fillers, therefrom is retarded by the addition of a silicate obtained by hydrothermal treatment of a silica-containing natural substance with an alkaline earth metal hydroxide, or of a silicate or silica thus produced and subsequently reacted with an acid or acidic substance (see Group III).  Specification 804,834 [Group III] is referred to.ALSO:Liquids such as glycol or glycerine suitable for use in cosmetics or in dentifrices, and ethereal oils suitable for use as additives to powder, may be thickened by the addition of a silicate obtained by hydrothermal treatment of a silica-containing natural substance with an alkaline earth metal hydroxide, or thickened with a silicate or silica thus produced and subsequently reacted with an acid or acidic substance (see Group III).  Specification 804,834, [Group III], is referred to.
PROBLEM TO BE SOLVED: To obtain an intestinal right place release preparation capable of selectively delivering medicines to the large intestine or the like by coating a drug-containing core substance with a mixed hydrophobic organic compound- enteric polymer film. SOLUTION: This preparation is obtained by coating (A) a drug (e.g. prednisolone or the like) containing core substance with a mixed (B) hydrophobic organic compound-(C) enteric polymer film. In the mixed film, the compound used as the component B is selected from a 6-22C (unsaturated bond may be included) higher fatty acid (e.g. stearic acid or the like), a 6-22C (unsaturated bond may be included) higher alcohol, a 6-22C (unsaturated bond may be included) higher fatty acid triglyceride or a (hydrogenated) natural oil and fat, and the compound used as the component C is selected from an enteric cellulose derivative, an enteric acrylic acid-based copolymer (e.g. methyl acrylate- methacrylic acid copolymer or the like), an enteric maleic acid-based copolymer, an enteric polyvinyl derivative or a shellac.  In particular, a stearic acid- methacrylic acid-methyl methacrylate copolymer or the like is favorable and the mixing ratio of the components B to C is preferably 5:95 to 95:5 in the weight ratio.
Opioid use disorder (OUD) is a chronic, relapsing disease and a major source of morbidity and mortality in the United States. Medications for opioid use disorder (i.e., methadone; buprenorphine) have been shown to reduce opioid use in diverse populations; however, long-term use of these medications and engagement in care are often suboptimal. Depression has been shown to contribute to medication discontinuation and care disengagement. Behavioral activation (BA) therapy is an evidence-based, behavioral treatment that has been shown to be effective in treating comorbid depression and substance use in diverse populations with smoking, alcohol, stimulant, and poly-substance use disorder. BA utilizes therapeutic techniques that help patients gradually increase goal-directed, potentially rewarding and pleasurable activities while decreasing the intensity and frequency of adverse events and consequences in order to improve mood. Given that BA utilizes strategies that can support individuals in alleviating depression and build the capacity to navigate life challenges, pairing BA with medications for OUD could help to ensure continued engagement in care and improve OUD treatment outcomes.

This study, therefore, seeks to determine the feasibility of study procedures, enhance participant acceptability, and demonstrate preliminary efficacy of the CoMBAT (Combined Medication and Behavioral Activation Treatment) intervention. The investigators will enroll individuals currently being treated with methadone or buprenorphine for OUD in a pilot randomized controlled trial (RCT) of the CoMBAT intervention. Prior to randomization, participants will receive 2 health navigation and standard substance abuse counseling sessions. Participants will then be equally randomized to either: 1) the 8-session CoMBAT intervention; or 2) standard of care. The primary outcome is engagement in care. Secondary outcomes include self-reported days of opioid use and opioid-positive urinalysis. Intervention feasibility and acceptability will also be assessed. Participants will complete major assessment visits (survey and toxicology testing) at baseline and 3- and 6-months post-randomization.
Patients in the intervention group received music therapy in 10-minutes sessions with the support of a specialist using the Turkish classical music (Hejaz and Rast modes) accompanied by a tambour. All forms were applied to the group before the music therapy, respectively. Prior to musical therapy, the patient's preferred classical music (Rast or Hejaz modes) was asked by the specialist and 10 minutes of music therapy was performed according to patient's choice. Clinical data and pain scores were obtained 5, 30 and 60 minutes after music therapy. 6 sessions of music therapy were applied on different days. Patient Follow-up Form was recorded before and after each therapy. The forms were evaluated 3 times, before the application, after the 3rd and 6th application.
The present invention provides an application of apple polyphenols which is separated and extracted from pomace, in preparation of drugs or health care products for prevention and treatment of osteoporosis. The characteristic of the invention is that apple polyphenols are applied to the preparation of drugs or health care products for prevention and treatment of osteoporosis. The apple polyphenols of the invention is separated and extracted from pomace, and used for prevention and treatment of osteoporosis. The waste use of the pomace is solved. The manufacturing cost of apple polyphenols is reduced. The environment pollution is reduced.
All subjects participate in testing that involves questionnaires, cognitive testing, fall risk assessment, and other testing related to physical parameters including body mass index, glycosylated hemoglobin, lower extremity nerve conduction study, and ankle range of motion, proprioception and strength. After testing, subjects are interviewed to determine fall status (faller or non-faller). A "faller" is defined as someone that has fallen at least 2 times in the past year. Data Analysis: The validity of the fall risk assessment tools will be compared using sensitivity and specificity analyses. Variables related to ankle function, neuropathy, glycemic control and general activity will be analyzed for association with recent fall history through multivariable logistic regression. Variables related to falls, neuropathy and activity level will be analyzed for association with health-related quality of life through multivariable linear regression.
The expression of a mRNA encoding a putative 76 amino acid, secreted protein ('Swirl') was found to negatively correlate with fasting triglyceride and cholesterol levels. A recombinant adenovirus was used to increase the expression of Swirl mRNA in two mouse models of obesity, KK-Ay and Lepob/Lepob mice. Over-expression of Swirl by adenovirus injection significantly, and reproducibly, reduced fasting triglyceride and cholesterol levels in both models. In addition, transgenic mice strains were made that over express Swirl protein. The expression of a key gene involved in lipogenesis (fatty acid synthase) and FAS protein levels were reduced by SWIRl adenoviral treatment in Lepob/Lepob mice. Full-length SWIRl peptide, or peptide derivatives, homologues, analogues, or mimetics thereof, delivered by oral intake, injection, subcutaneous patch, or intranasal routes, could be used as therapeutic or diagnostic agents for hypercholesterolemia, hypertriglyceridemia, insulin resistance, obesity, diabetes, and/or energy imbalance.
Ampullary neoplasms remain rare, with a reported prevalence of 0.04% to 0.12% in autopsy studies. , endoscopic papillectomy is now recognized as a safe and reliable alternative to surgery for ampullary adenomas and is associated with high success rates (72%-95%), low morbidity (10%-30%), and minimal mortality (0.2%-1%). Typically, however, intrabiliary extension of the adenoma has been regarded as a contraindication for endoscopic papillectomy. Surgical referral is therefore recommended with intraductal extension, particularly when the length of extension exceeds 1 cm. Radiofrequency ablation offers a potentially safe and effective treatment for malignant biliary strictures. The use of RFA as a primary treatment for intraductal dysplasia after endoscopic papillectomy has been shown in few small case series to be feasible with the primary limitation of short follow-up periods. The primary aim of this study was to describe our experience with RFA in patients with ampullary neoplasia and associated intraductal extension who were not surgical candidates.
PURPOSE: Provided are radioactive magnetic fluids, a process for preparing the same and the use thereof. In particular, the radioactive magnetic fluids are used for treatment or diagnosis of cancers. Therefore, the treatment efficiency of cancers is increased, while lowering adverse side effects, such as apoptosis of normal cells. CONSTITUTION: The radioactive magnetic fluids are prepared by coating a nano particle of magnetite containing divalent copper ion with surfactants. The nano particle of magnetite is CuxFe1-xO.Fe2O3, wherein x ranges within 0.1-0.4. And the surfactants are decanoic acid and nonanoic acid. The therapeutics and diagnosis agents for cancers contain the radioactive magnetic fluids.
A system for providing a community in which treatments may be tested for conditions associated with one or more entities. Information may be received that includes a condition of an entity, the condition associated with a particular domain, and one or more symptoms of the condition experienced by the entity. Access to the information may be provided to one or more domain experts. The provision of one or more treatments for the condition to the community may be facilitated. The treatment of the condition may be tracked and analyzed for efficacy. Treatment plans may be suggested for conditions based on the analysis of the information provided to the community.
Groin wound infection after vascular surgery is a frequent complication with a significant increase in post operative morbidity and mortality. Actual studies reported more than 20% of patients who develop groin wound infection with an important rate of reintervention and risk in limb loss. Theses groin complications are frequent in drug abusers but can also happen after percutaneous femoral access for endovascular therapy leading to arterial reconstruction.

After mechanical debridement and eventually muscle flap rotation, ESVS 2020 guidelines recommend in situ reconstruction with the use of autogenous reconstruction vein femoral vein but it is a demanding surgery especially in redo surgery with extensive incision and deep venous complication. Saphenous vein is often too small in diameter to perform a femoro-femoral reconstruction. The other possibility is cryopreserved Cadaveric Arterial Allograft which are difficult to obtain in sufficient time for an urgent operation with frequent aneurysmal evolution. Literature reports up to 30% of reinfection with rifampin-soaked Dacron conduit are used with frequent reintervention. Rolled Bovine pericardium grafts have been proposed as a primary intention substitute in native and prosthetics aortic infections and are presented as resistant to infection when used as patch repair in case of groin complications. The aim of our study was to evaluate the outcomes in term of patency, limb salvage and infection resistance of this substitute when tubulized with stample in groin wound infection to replace previous prosthetic graft with active infection or false aneurysm rupture or after percutaneous septic femoral access complication in emergency surgery.
A skin care formulation includes azelaic acid. The skin care formulation also includes a first booster composition including at least one first active booster ingredient. The skin care formulation further includes a second booster composition including at least one second active booster ingredient. The skin care formulation is a water-based emulsion that is stable for at least 3 months. A method of forming a skin care formulation includes combining an anti-acne booster composition, a first booster composition, a second booster composition, and an aqueous base composition to form the skin care formulation. The anti-acne booster composition includes azelaic acid.
Nisoldipine is a member of the dihydropyridine class of calcium channel antagonists (calcium ion antagonists or slow channel blockers) that inhibit the transmembrane influx of calcium into vascular smooth muscle and cardiac muscle. It reversibly competes with other dihydropyridines for binding to the calcium channel. Because the contractile process of vascular smooth muscle is dependent upon the movement of extracellular calcium into the muscle through specific ion channels, inhibition of the calcium channel results in dilation of the arterioles. In vitro studies show that the effects of nisoldipine on contractile processes are selective, with greater potency on vascular smooth muscle than on cardiac muscle. Although, like other dihydropyridine calcium channel blockers, nisoldipine has negative inotropic effects in vitro, studies conducted in intact anesthetized animals have shown that the vasodilating effect occurs at doses lower than those that affect cardiac contractility.  
  
The effect of nisoldipine on blood pressure is principally a consequence of a dose-related decrease of peripheral vascular resistance. While nisoldipine, like other dihydropyridines, exhibits a mild diuretic effect, most of the antihypertensive activity is attributed to its effect on peripheral vascular resistance.
A method for monitoring an individual's drug regimen and meal regimen to reduce the likelihood of a drug-to-food interaction. An ingredient group table is constructed that includes ingredient groups which are known to cause an adverse reaction when combined with a particular drug in an individual. Known drugs are linked to contraindicated ingredient groups listed in the ingredient group table to create a drug-ingredient group table, which includes the known drugs and the linked contraindicated ingredient groups. The drug regimen of an individual is determined from a Physicians' Orders database. The drug-ingredient group table is searched using the individual's drug regimen as the search criteria. Matching drugs along with the linked contraindicated ingredient groups are extracted from the drug-ingredient group table and placed in a personalized drug-ingredient group table. A personalized contraindicated ingredient group table is created by extracting the contraindicated ingredient groups of the personalized drug-ingredient group table. Food items from an institutions menu are linked to the ingredient groups of the ingredient group table to create a food-ingredient group table, which includes the food items and the linked ingredient groups. The meal regimen of an individual is determined from dietary software or other means. The food-ingredient group table is searched using the individual's meal regimen as the search criteria. Matching food items along with the linked ingredient groups are extracted from the food-ingredient group table and placed in a personalized food-ingredient group table. The ingredient groups linked to each food item of the personalized food-ingredient group table are compared to the personalized contraindicated ingredient group table. If there are one or more matching ingredient groups between the two tables, a contraindication warning is issued. If there are no matching ingredient groups, then the meal may be served to the individual.
Systems and methods are provided for intraoperative real-time clinical decision support. A system includes a processor, a non-transitory computer readable medium, storing executable instructions, and an output device. An interface is configured to receive a first set of patient data in real-time from at least one sensor monitoring vital signals of a patient during a surgical procedure and a second set of patient data in real-time from an anesthesia machine during the surgical procedure. An input interface receives an indicator representing at least an identity of a therapeutic to be administered to the patient. A machine learning model determines from the indicator, the first set of patient data, and the second set of patient data if an alert should be provided to a user. The output device provides the alert to the user if the machine learning model determines that the alert should be provided.
BACKGROUND AND PURPOSE: Precise and timely diagnosis is crucial for the optimal use of emerging disease-modifying treatments for Alzheimer disease (AD). Electroencephalography (EEG), which is noninvasive and cost-effective, can capture neural abnormalities linked to various dementias. This study explores the use of individual alpha frequency (IAF) derived from EEG as a diagnostic and prognostic tool in cognitively impaired patients.
METHODS: This retrospective study included 375 patients from the tertiary Memory Clinic of IRCCS San Raffaele Hospital, Milan, Italy. Participants underwent clinical and neuropsychological assessments, brain imaging, cerebrospinal fluid biomarker analysis, and resting-state EEG. Patients were categorized by amyloid status, the AT(N) classification system, clinical diagnosis, and mild cognitive impairment (MCI) progression to AD dementia. IAF was calculated and compared among study groups. Receiver operating characteristic (ROC) analysis was used to calculate its discriminative performance.
RESULTS: IAF was higher in amyloid-negative subjects and varied significantly across AT(N) groups. ROC analysis confirmed IAF's ability to distinguish A-T-N- from the A+T+N+ and A+T-N+ groups. IAF was lower in AD and Lewy body dementia patients compared to MCI and other dementia types, with moderate discriminatory capability. Among A+ MCI patients, IAF was significantly lower in those who converted to AD within 2 years compared to stable MCI patients and predicted time to conversion (p < 0.001, R = 0.38).
CONCLUSIONS: IAF is a valuable tool for dementia diagnosis and prognosis, correlating with amyloid status and neurodegeneration. It effectively predicts MCI progression to AD, supporting its use in early, targeted interventions in the context of disease-modifying treatments.
Patients undergo 12 sessions of percutaneous electrical stimulation of dermatome T6 (PENS T6), weekly, during 12 weeks. During this period they follow a hypocaloric 1200 Kcal/day diet.
List of 10 specific situations that can act as anger triggers and 10 strategies. Participants are instructed to select most encountered triggers and most useful strategies.
PROBLEM TO BE SOLVED: To easily refer to various pieces of medical information corresponding to patients by installing item folders for individual reference items and patient folders for individual patients in a storage means hierarchically, giving patient ID for identifying the patients to the folder name of the patient folder, reading the medical information of the patient from the storage means on the basis of the folder name and displaying it. SOLUTION: Various medical information on patients are preserved, on the basis of a reference item, patient ID and date/time. A medical record number (patient ID) identifying the patient is received (S1). Then, the reference item is received (S2). An item folder corresponding to the received reference item is retrieved by using an item folder name, and a patient folder corresponding to the patient ID is retrieved according to a patient folder name (S3). A date/ time folder, where latest medical information is stored, is retrieved according to the date/time folder name, and the medical information stored in the retrieved date/time folder is displayed (S4).
Glucose levels are being measured by the AccuChek. Patients also get a Freestyle Navigator, which will be blinded. The device will stay on the patient up to 5 days, or until discharge from the ICU.
This study is a double-blind randomized controlled trial aimed at evaluating the effectiveness of MT compared to a control group for major depressive disorder.

Participants will be randomly assigned in a 1:1 ratio to the MT group or control group. All participants will receive 12 sessions (3 sessions per week), each lasting 30 minutes, over a 4-week period. The MT group will receive music therapy during the first 4 weeks, while the control group will receive music therapy during the subsequent 4 weeks (weeks 5-8). Prior to the start of the study (baseline) and after the 4-week intervention, both groups will undergo symptom assessments and brain imaging (MRI) to collect data. The MT intervention consists of three stages, each with a specific focus: 1) physical and mental relaxation, which involves learning relaxation techniques from breathing to muscle relaxation; 2) nature imagination, which includes guided music imagery; and 3) internal self-exploration, which involves identifying positive experiences and potential resources for psychological intervention. The study aims to: 1) assess the clinical efficacy of MT in reducing depressive symptoms, and 2) examine possible biological mechanisms underlying the effectiveness of MT through multidimensional analysis of neuroimaging data and acoustic feature alterations.